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Abstract
Background: The role of surgical intervention as a treatment for pulmonary metastasis (PM) from hepatocellular
carcinoma (HCC) has not been established. In this study, we investigated the clinical outcomes of pulmonary
metastasectomy. Using propensity score matching (PSM) analysis, we compared the results according to the
surgical approach: video-assisted thoracic surgery (VATS) versus the open method.
Methods: A total of 134 patients (115 men) underwent pulmonary metastasectomy for isolated PM of HCC
between January 1998 and December 2010 at Seoul Asan Medical Center. Of these, 84 underwent VATS (VATS
group) and 50 underwent thoracotomy or sternotomy (open group). PSM analysis between the groups was used to
match them based on the baseline characteristics of the patients.
Results: During the median follow-up period of 33.4 months (range, 1.8–112.0), 113 patients (84.3%) experienced
recurrence, and 100 patients (74.6%) died of disease progression. There were no overall survival rate, disease-free
survival rate, and pulmonary-specific disease-free survival rate differences between the VATS and the open groups
(p = 0.521, 0.702, and 0.668, respectively). Multivariate analysis revealed local recurrence of HCC, history of liver
cirrhosis, and preoperative alpha-fetoprotein level as independent prognostic factors for overall survival (hazard
ratio, 1.729/2.495/2.632, 95% confidence interval 1.142–2.619/1.571–3.963/1.554–4.456; p = 0.010/< 0.001/< 0.001,
respectively).
Conclusions: Metastasectomy can be considered a potential alternative for selected patients. VATS metastasectomy
had outcomes comparable to those of open metastasectomy.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most fre-
quent malignancies in Asia, including Korea [1], and ranks
third in cancer deaths worldwide [2]. In the recent years,
the postoperative morbidity and mortality rates from
HCC have improved; however, long-term outcomes re-
main poor due to extrahepatic metastasis and intrahepatic
recurrence after surgical management. The most frequent
site of metastasis and of the first detectable metastasis was
reported to be the lungs [3, 4]. However, appropriate man-
agement for pulmonary metastasis (PM) has not been
established, and systemic chemotherapy has been reported
to be largely ineffective [5]. The results of the multi-
national, randomized, placebo-controlled, phase III sorafe-
nib HCC Assessment Randomized Protocol (SHARP) trial
demonstrated that sorafenib significantly improved the
overall survival in patients with advanced HCC and well-
preserved liver function, and that drug-related adverse
events were manageable [6]. However, according to the
subanalysis of phase II sorafenib Asia-Pacific trial, the ef-
fectiveness of sorafenib in advanced HCC patients remains
unclear as the survival gain in patients with PM was only
1.4 months (hazard ratio [HR] 0.87) [7]. Although sorafe-
nib has been a standard regimen for advanced HCC, its ef-
fectiveness is marginal in the presence of PM. In most
cases, the lesions of extrahepatic metastasis from HCC are
not resectable. Therefore, surgical treatment of PM has
not been applied as a standard therapy in PM from HCC.
In some reports, pulmonary resection for PM from
HCC resulted in long-term survival in highly selected
patients [8–10]. Usually, wedge resection through open
thoracotomy has been performed for superficial lesions,
and segmentectomy or lobectomy is needed for deeper
lesions. With recent advances in VATS and diagnostic
modalities, such as multi-detector row computed tomog-
raphy (CT), minimally invasive and complete metasta-
sectomy can be provided to chronically ill patients with
HCC and PM [1–14]. However, the use of surgical re-
section and VATS for PM of HCC remains controver-
sial. We believe that an appropriate surgical role is
needed for the treatment of patients with advanced
HCC. In this study, we investigated the clinical out-
comes of pulmonary metastasectomy and the risk factors
for survival rate and disease-free survival rate in patients
of HCC with PM. Using propensity score matching
(PSM) analysis, we compared the results according to




In this study, we retrospectively reviewed a total of 1085
patients who had undergone metastasectomy due to
thoracic metastasis from HCC between January 1998
and December 2010. Of these, 852 cases with different
histology and 18 cases with metastatic lesions in the
thorax other than the lung were excluded. Sixty-one
cases were further excluded due to duplicated patients.
Ten patients had concurrent malignancies, and 3 cases
were diagnosed with a different histology from HCC.
After excluding 7 cases with incomplete medical records,
we retrospectively 134 patients (115 men) who had
undergone pulmonary metastasectomy for isolated PM
of HCC. The enrollment of patients is shown in Fig. 1.
The inclusion criteria of our study were as follows: (1)
controlled state of primary HCC, (2) no other distant
metastasis, and (3) appropriate pulmonary function test
for major lung resection. All patients had available
follow-up till December 2015.
Methodology
Eighty-four patients underwent VATS (VATS group), and
50 underwent thoracotomy or sternotomy (open group).
Under general anesthesia and double-lumen endotracheal
tube insertion for single-lung ventilation, the patients’
chest that is where the lesion is located was up on the de-
gree of 90°. Three or four surgical ports were created for
VATS, and posterolateral thoracotomy or median sternot-
omy was performed for open surgery. Surgical approaches
such as thoracotomy, sternotomy, and VATS were deter-
mined depending on the size, number, location, and lat-
erality of the metastatic nodules. VATS can be applied for
lesions of sizes below 3 cm, located in the outer one-third
of the lung, having no endobronchial extension. The
metastatic lesion located in the periphery of the lung was
non-problematically resected by wedge resection. Segmen-
tectomy or lobectomy was needed for deeply located le-
sions. Mediastinal lymph node dissections were
performed only if enlarged lymph nodes were revealed on
chest CT. This study was approved by the Asan Medical
Center Ethics Committee/Review Board (2019-1166).
Statistical analysis
Time-to-pulmonary recurrence after the initial treat-
ment (TPR) was defined as the interval between control
of HCC and the diagnosis of PM. Disease-free survival
(DFS) after the first pulmonary metastasectomy was de-
fined as the interval between the first pulmonary metas-
tasectomy and diagnosis of a lesion related to HCC after
the first pulmonary metastasectomy. Pulmonary DFS
after metastasectomy (PDFS) was defined as the interval
between the first pulmonary metastasectomy and the
diagnosis of the second PM. Overall survival time was
measured by comparing the date of the first pulmonary
metastasectomy to the date of death or the last follow-
up. Preoperative alpha-fetoprotein (AFP) was defined as
the value of the latest serum AFP level measured before
the first metastasectomy. Postoperative AFP was defined
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as the value of the earliest measured serum AFP level
after the first metastasectomy, within 2 months. The cal-
culation of the BCLC stage was based on before lung
metastasis was detected. This is because, based on the
time after lung metastasis is found, all patients are at
BCLC stage c or higher, and other variables of the pa-
tient before surgery may not be considered. Categorical
variables were expressed as frequencies and percentages
and were compared between the two approaches using
the chi-square test or Fisher’s exact test. Continuous
variables were shown as means with standard deviations
or median values with range and were compared using a
Student’s t test. Univariate and multivariate analyses for
prognostic factors were performed using Cox’s propor-
tional hazard model. Survival rates were estimated using
the Kaplan-Meier method, and survival according to the
prognostic factors was compared using a log-rank test.
Cox proportional hazard models were used to identify
the predictors of mortality and recurrence. After exclud-
ing the correlated variables, independent variables with
p values ≤ 0.05 from the univariate analysis were used
for the initial multivariate Cox. The final multivariable
model was selected using forward stepwise selection (p
value ≤ 0.10 for entering the model and p ≤ 0.05 for
staying in the model).
There were several considerations (baseline character-
istics, HCC factors, surgical factors) for PSM; 13 vari-
ables (age, sex, history of liver cirrhosis, level of initial
AFP, etiology of HCC, BCLC stage of HCC, Child-Pugh
score, Eastern Cooperative Oncology Group (ECOG)
scale of performance status, treatment method for pri-
mary HCC, local recurrence or progression of HCC,
number of PM, maximum diameter of PM, TPR) were
used for PSM. For PSM, observation pairs with equiva-
lent propensity scores were selected with nearest-
neighbor matching and a caliper width of 0.2 standard
deviation. Patients in the VATS group were randomly
matched to patients in the open group at a ratio of 1:1.
The final sample consisted of 32 matched patients in
each group.
Statistical analyses were performed using SPSS version
21.0 (SPSS Inc. Armonk, NY, USA) and R version 3.4.2
(R Project for Statistical Computing, Vienna, Austria). A
value of p < 0.05 was considered statistically significant.
Results
The median age was 55.0 years (range, 24–76 years). Pa-
tient characteristics are summarized in Table 1.
Surgical treatment for primary HCC was performed in
107 patients (79.9%), liver cirrhosis was reported in 49
Fig. 1 The enrollment of patients
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patients (36.6%), and local recurrence of HCC was found
in 89 patients (66.4%). There were no significant differ-
ences in baseline and primary HCC characteristics be-
tween the VATS and open groups. Unilateral PM was
found in 104 patients (77.6%), and the median number of
PMs was 1.0 (range, 1–11). There was a significant differ-
ence in the size and number of metastatic nodules be-
tween the VATS and open groups (p = 0.039 and 0.009,
respectively). Wedge resection was more frequently per-
formed in the VATS group than in the open group. There
was no operative mortality. The median overall survival
time was 38.7months (range, 4.4–172.3), and median TPR
was 19.1months (range, 5–95.9). Perioperative complica-
tions occurred in 6 (4.5%). Three patients had prolonged
pleural effusion needing insertion of the chest tube, 2
patients had prolonged air leakage, and 1 patient had post-
operative pneumonia. The median hospital days after
metastasectomy was 5 days (range, 3–26), 4.0 days (range,
3–24) in the VATS group, and 7.0 days (range, 4–26) in
the open group (p = 0.001) (Table 2).
For the median 33.4 months (range, 1.8–112.0) dur-
ation of the follow-up from first metastasectomy, 113
(84.3%) patients experienced recurrence: 63 (55.7%) in
the lung, 26 (23.0%) in the liver, 2 (1.8%) in the brain, 13
(11.5%) in other single organs, and 9 (8.0%) in multiple
organs. Pulmonary-specific recurrences were observed in
95 (70.9%) patients. Forty-three (45.3%) patients had
ipsilateral pulmonary metastases. Forty-five (47.4%) pa-
tients underwent repeated metastasectomies, 27 (28.4%)
patients received chemotherapy, 4 (4.2%) patients
Table 1 Patients’ baseline and primary hepatocellular carcinoma characteristics
Total (n = 134) Open (n = 50) VATS (n = 84) p value
Age (years) 54.4 ± 9.5 53.1 ± 9.2 55.1 ± 9.7 0.261
Sex (male) 115 (85.8%) 45 (90.0%) 70 (83.3%) 0.285
BCLC stage 0.206
0 4 (3.0%) 0 4 (4.8%)
A 34 (25.4%) 15 (30.0%) 19 (22.6%)
B 49 (36.6%) 18 (36.0%) 31 (36.9%)
C 43 (32.1%) 14 (28.0%) 29 (34.5%)
D 4 (3.0%) 3 (6.0%) 1 (1.2%)
ECOG performance status 0.571
0 112 (83.6%) 41 (82.0%) 71 (84.5%)
1 17 (12.7%) 6 (12.0%) 11 (13.1%)
2 4 (3.0%) 2 (4.0%) 2 (2.4%)
3 1 (0.7%) 1 (2.0%) 0
4 0 0 0
Etiology 0.716
HBV 111 (82.8%) 42 (84.0%) 69 (82.1%)
HCV 1 (0.7%) 0 1 (1.2%)
Alcohol 5 (3.7%) 1 (2.0%) 4 (4.8%)
Unknown 17 (12.7%) 7 (14.0%) 10 (11.9%)
Child-Pugh classification 0.422
A 116 (86.6%) 41 (82.0%) 75 (89.3%)
B 13 (9.7%) 6 (12.0%) 7 (8.3%)
C 5 (3.7%) 3 (6.0%) 2 (2.4%)
Liver cirrhosis 49 (36.6%) 14 (28.0%) 35 (41.7%) 0.112
Initial AFP (ng/ml) 73.0 (1.0–585,000) 60.7 (1.0–585,000) 80.0 (1.0–485,000) 0.601
Treatment of HCC 0.171
Surgery 107 (79.9%) 43 (86.0%) 64 (76.2%)
TACE 27 (20.1%) 7 (14.0%) 20 (23.8%)
RFA 0 0 0
VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, PSM propensity score
matching, ECOG Eastern Cooperative Oncology Group, TACE transarterial chemoembolization, RFA radiofrequency ablation
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received radiation therapy, 2 (2.1%) patients received
chemoradiation therapy, and in 17 (17.9%) patients,
metastatic lesions remained for various reasons (Table
3). One hundred patients (74.6%) died of disease pro-
gression. The 1-, 3-, and 5-year overall survival rates
after the first pulmonary metastasectomy were 85.8%,
53.7%, and 37.3%, respectively. Disease-free survival rates
after the first pulmonary metastasectomy were 33.2% in
1 year, 23.7% in 3 years, and 20.4% in 5 years, respect-
ively (Fig. 2).
Table 2 Characteristics of the first pulmonary metastasectomy
Total (n = 134) Open (n = 50) VATS (n = 84) p value
Preoperative AFP (ng/ml) 18.9 (1.1–12,000.0) 34.9 (1.1–7330.0) 9.9 (1.2–12000.0) 0.155
Postoperative AFP (ng/ml) 10.6 (0–28,200.0) 11.8 (0–28,200.0) 8.8 (0–18,800.0) 0.193
Local recurrence 73 (50.3%) 33 (66.0%) 40 (47.6%) 0.112
Progression of local disease 16 (11.0%) 5 (10.0%) 11 (13.1%)
Laterality 0.039
Bilateral 30 (22.4%) 16 (32.0%) 14 (16.7%)
Unilateral 104 (77.6%) 34 (68.0%) 70 (83.3%)
Number of metastasis 1.8 ± 1.4 2.2 ± 1.9 1.5 ± 0.9 0.009
Size (mm) 14.9 ± 9.4 16.4 ± 8.1 14.0 ± 10.0 0.143
Extent of resection 0.001
Wedge resection 104 (77.6%) 30 (60.0%) 74 (88.1%)
Segmentectomy/lobectomy 30 (22.4%) 20 (40.0%) 10 (11.9%)
Hospital stay (days) 6.4 ± 4.2 7.9 ± 4.0 5.4 ± 4.1 0.001
Complications 6 (4.5%) 4 (8.0%) 2 (2.4%) 0.195
DFI from HCC (months) 22.6 ± 17.2 21.8 ± 16.4 23.1 ± 17.7 0.666
DFI from PM (months) 22.3 ± 39.4 22.6 ± 43.7 22.2 ± 36.9 0.945
Overall survival time (months) 52.1 ± 41.0 56.4 ± 46.6 49.5 ± 37.3 0.377
VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, PM pulmonary metastasis, DFI disease-free interval
Table 3 Recurrence of metastasis from hepatocellular carcinoma after the first pulmonary metastasectomy
Total (n = 134) Open (n = 50) VATS (n = 84) p value
Recurrence after metastasectomy 113 (84.3%) 42 (84.0%) 71 (84.5%) 0.936
Recurred site 0.581
Lung 63 (47.0%) 27 (54.0%) 36 (42.9%)
Liver 26 (19.4%) 9 (18.0%) 17 (20.2%)
Bone 0 0 0
Brain 2 (1.5%) 1 (2.0%) 1 (1.2%)
Different single organ 13 (9.7%) 2 (4.0%) 11 (13.1%)
Multiple organs 9 (6.7%) 3 (6.0%) 6 (7.1%)
Pulmonary specific recurrence 95 (70.9%) 38 (76.0%) 57 (67.9%) 0.316
Recurred site 0.297
Ipsilateral 43 (32.1%) 20 (40.0%) 23 (27.4%)
Contralateral 52 (38.8%) 18 (36.0%) 34 (40.5%)
Treatment of recurred PM 0.533
Surgery 45 (33.6%) 18 (36.0%) 27 (32.1%)
Chemotherapy 27 (20.1%) 10 (20.0%) 17 (20.2%)
Radiotherapy 4 (3.0%) 2 (4.0%) 2 (2.4%)
Chemoradiation 2 (1.5%) 2 (4.0%) 0
Observation 17 (12.7%) 6 (12.0%) 11 (13.2%)
VATS video-assisted thoracic surgery, PM pulmonary metastasis
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Local recurrence of HCC, history of liver cirrhosis,
and preoperative AFP were found to be independent
prognostic factors for overall survival (Table 4). Local
recurrence of HCC and TPR were independent prog-
nostic factors for DFS after the first pulmonary
metastasectomy (p < 0.001 and 0.005, respectively)
(Table 5). For pulmonary-specific recurrence, local re-
currence of HCC and preoperative AFP were inde-
pendent prognostic factors (p < 0.001 and p = 0.013,
respectively) (Table 6).
The patients’ characteristics after PSM are summa-
rized in Table 7. No significant differences in baseline
and PM characteristics were observed. The open group
underwent more extensive surgery and stayed more days
than the VATS group (p = 0.025 and p = 0.017, respect-
ively) (Table 8). There was no significant difference in
overall survival rate, DFS rate, and PDFS rate after the
first pulmonary metastasectomy between the VATS and
open groups (p = 0.764, 0.937, and 0.786, respectively)
(Fig. 3).
Discussion
The survival rate of HCC patients has markedly im-
proved as a result of advances in surgical techniques and
perioperative management. Although the lung is the
most frequent site of extrahepatic metastasis from
HCC, the role of surgery for PM from HCC has not
been fully clarified yet, unlike PM from colorectal
cancer or osteosarcoma. There have been some re-
ports favoring surgical resection for isolated PM from
HCC, and the present study supports those results
[8–10]. While median survival time and 1-year sur-
vival rate of the patients with PM treated with
chemotherapy were 4.6–14 months and 20–42%, re-
spectively [5, 8], 5-year survival rate of patients who
had undergone metastasectomy was reported to be
24–41.4% [15–20].
In the present study, the 5-year DFS rate and 5-year
survival rate were 20.4% and 37.3%, respectively. More
long-term survivors could be found among the patients
who underwent metastasectomy than among those who
received chemotherapy. However, since most studies
were non-randomized and included only operable and
resectable lesions in the surgery group, a comparison of
outcomes between metastasectomy and chemotherapy
needs circumspection.
Cheng et al. reported the overall survival of patients
with advanced HCC with or without sorafenib. The me-
dian overall survival period was 6.5 and 4.2 months [7].
In our study, the median overall survival period was
Fig. 2 Survival rate from the first pulmonary metastasectomy in all patients; overall survival rate (a) and disease-free survival rate (b)
Lee et al. World Journal of Surgical Oncology           (2021) 19:33 Page 6 of 12
38.7 months (range, 4.4–172.3). There are quite a few
differences between the two studies. The reason being
that the previous study included patients who were not
subjected to surgery.
In this series, 81 (60.4%) patients had a single PM,
while only 6 (4.5%) patients had five or more PMs. This
implies that patients with a less invasive disease could be
selected for metastasectomy. One hundred and thirty pa-
tients with four or less PMs showed a median survival
period of 40.7 months (range, 4.4–172.3) regardless of
the number of PMs. To evaluate the efficacy of metasta-
sectomy, large randomized studies are needed.
Surgical intervention for PM can provide excellent
local control. Due to its low mortality and morbidity
Table 4 Univariate and multivariate analysis for overall survival after the first pulmonary metastasectomy
Characteristics Univariate Multivariate
p value HR (95% CI) p value
Age > 50 years 0.375
Liver cirrhosis (+) 0.051 1.729 (1.142–2.619) 0.010
Hepatitis viral marker (+) 0.457
BCLC stage ≥ C 0.035
ECOG performance status ≥1 0.089
Child-Pugh score ≥ B 0.025
Local recurrence of HCC < 0.001 2.495 (1.571–3.963) < 0.001
Initial AFP > 500 ng/ml 0.318
Preoperative AFP > 500 ng/ml < 0.001 2.632 (1.554–4.456) < 0.001
Wedge resection as metastasectomy 0.423
Multiple PM 0.274
Maximum diameter of PM > 2 cm 0.130
Hospital days ≥ 7 0.093
Time-to-pulmonary recurrence period 0.113
Open metastasectomy 0.870
HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative
Oncology Group, PM pulmonary metastasis
Table 5 Univariate and multivariate analysis for disease-free survival after the first pulmonary metastasectomy
Characteristics Univariate Multivariate
p value HR (95% CI) p value
Age > 50 years 0.464
Liver cirrhosis (+) 0.173
Hepatitis viral marker (+) 0.627
BCLC stage ≥ C 0.072
ECOG performance status ≥1 0.161
Child-Pugh score ≥ B 0.120
Local recurrence of HCC < 0.001 2.717 (1.694–4.357) < 0.001
Initial AFP > 500 ng/ml 0.910
Preoperative AFP > 500 ng/ml 0.037
Wedge resection as a metastasectomy 0.199
Multiple PM 0.265
Maximum diameter of PM > 2 cm 0.387
Hospital days ≥ 7 0.044
Time-to-pulmonary recurrence period 0.068 1.852 (1.204–2.848) 0.005
Open metastasectomy 0.943
HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative
Oncology Group, PM pulmonary metastasis
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[15–20], metastasectomy should be considered as a vi-
able option to prevent pulmonary complications caused
by PM. Several studies suggest that to improve long-
term survival, patients with isolated PM and no other
distant metastasis should be considered not only for
surgical resection but also for repeated resection of PM
[21–23]. In our experience, patients who underwent
pulmonary metastasectomy could be discharged within
approximately 7 days without operative mortality or
serious complications. The second or third pulmonary
metastasectomy could also be safely performed, and
repeated metastasectomy could be attempted in pa-
tients with localized PM from HCC for better survival
(5-year survival rate was 59.1% in repeated metasta-
sectomy patients and 48.1% in non-surgical treatment
patients, p = 0.002).
Introduction of VATS makes metastasectomy more
endurable for patients with chronic diseases such as liver
cirrhosis. Less pain and shorter hospitalization can lead
to earlier returns to preoperative activities or subsequent
treatment [11–13, 24]. However, the inability to thor-
oughly palpate the lung by VATS raises concerns about
incomplete metastasectomy [25, 26] which could result
in significantly worse survival rates [27]. In contrast,
there are reports suggesting that the outcomes of thora-
coscopic surgery are not inferior to those of open thora-
cotomy [13, 28]. This disagreement can partly be due to
the possibility that finger palpation of the lung also has
limitations in terms of detecting small nodules; in
addition, metastasectomy under a thoracotomy is not
always complete [29]. Recently, in contrast to the in-
accuracy of old-generation CT, the 1-mm-thin section
16-channel multi-detector row CT showed a high detec-
tion rate of metastatic pulmonary nodules, especially in
patients with non-osteosarcoma. Therefore, it can be a
possible substitute for manual palpation [14]. If diagno-
sis by either imaging or palpation is incomplete, VATS
should be considered for metastasectomy. VATS can
minimize adhesion formation and render repeated re-
section more amenable. Given that complete resection
is most important in any situation, conversion to thora-
cotomy should be promptly considered if the lesions
detected by CT cannot be identified or resected by
VATS. In the present study, all preoperatively detected
PMs were completely resected either by VATS or by
open surgery. Hospitalization duration and complica-
tion rate were significantly reduced in the VATS group.
However, because more segmentectomies and lobecto-
mies were adapted in the open group, it is difficult to
compare the two methods straightforwardly. To over-
come the shortcomings outlined above, in the present
study, the propensity score matching analysis was
adapted to compare two methods, and relatively favor-
able results were observed. However, matched analysis
needs to drop unmatched data, for which, the main
drawback is the shortage of cases. For this reason,
further randomized large cohort studies need to be
conducted in the future.
Table 6 Univariate and multivariate analysis for pulmonary-specific disease-free survival after the first pulmonary metastasectomy
Characteristics Univariate Multivariate
p value HR (95% CI) p value
Age > 50 0.253
Liver cirrhosis (+) 0.216
Hepatitis viral marker (+) 0.628
BCLC stage ≥ C 0.023
ECOG performance status ≥1 0.020
Child-Pugh score ≥ B 0.156
Local recurrence of HCC < 0.001 3.105 (1.946–4.954) < 0.001
Initial AFP > 500 ng/ml 0.955
Preoperative AFP > 500 ng/ml 0.082 1.978 (1.157–3.382) 0.013
Wedge resection as metastasectomy 0.227
Multiple PM 0.156
Maximum diameter of PM > 2 cm 0.847
Hospital days ≥7 0.086
Time-to-pulmonary recurrence period 0.151
Open metastasectomy 0.578
HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative
Oncology Group, PM pulmonary metastasis
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In the published literature, only several studies have
reported risk factors related to long-term survival.
Complete resection is the most significant predictor
of better survival [18–20, 27]. Worse survival can be
expected for patients with the factors causing a rise
in the possibility of incomplete resection including
multiple lesions [16, 30] and the factors predicting
aggressive disease, such as short disease-free interval
[18–20, 27, 30–33], multiple PMs, and higher serum
AFP levels [19, 20]. It was suggested that the size of
nodules had an inverse correlation with survival in
PM from cancer other than HCC [22]. In the present
study, local recurrence or progression of HCC, history
of liver cirrhosis, and preoperative AFP were found to
be independent prognostic factors for overall survival
after the first pulmonary metastasectomy. Local recur-
rence or progression of HCC and preoperative AFP
were also found to be independent prognostic factors
for pulmonary-specific recurrence. Therefore, our re-
sults suggest that if there is a local recurrence or pro-
gression of HCC or if the levels of AFP before
surgery are high, decisions on surgical treatments
should be made with caution. The impact of all these
proposed factors needs to be verified in future large-
scale studies.
Conclusion
When metastasis confined to the lung with the HCC
under control or controllable, metatasectomy can be
Table 7 Baseline characteristics of open and VATS group after propensity score matching
Total (n = 58) Open (n = 29) VATS (n = 29) p value
Age (years) 54.0 ± 11.1 54.8 ± 9.3 53.2 ± 12.7 0.606
Sex (male) 51 (87.9%) 26 (89.7%) 25 (86.2%) 0.687
BCLC stage 0.284
0 0 0 0
A 13 (22.4%) 9 (31.0%) 4 (13.8%)
B 21 (36.2%) 9 (31.0%) 12 (41.4%)
C 24 (41.4%) 11 (38.0%) 13 (44.8%)
D 0 0 0
ECOG performance status 0.339
0 49 (84.5%) 24 (82.8%) 25 (86.2%)
1 7 (12.1%) 3 (10.3%) 4 (13.8%)
2 2 (3.4%) 2 (6.9%) 0
3 0 0 0
4 0 0 0
Etiology 0.362
HBV 46 (79.3%) 24 (82.8%) 22 (75.9%)
HCV 1 (1.7%) 0 1 (3.4%)
Alcohol 2 (3.4%) 0 2 (6.9%)
Unknown 9 (15.5%) 5 (17.2%) 4 (13.8%)
Child-Pugh classification 0.706
A 50 (86.2%) 24 (82.8%) 26 (89.7%)
B 8 (13.8%) 5 (17.2%) 3 (10.3%)
C 0 0 0
Liver cirrhosis 19 (32.8%) 11 (37.9%) 8 (27.6%) 0.401
Treatment of HCC 0.730
Surgery 48 (82.8%) 23 (89.3%) 25 (86.2%)
TACE 10 (17.2%) 6 (20.7%) 4 (13.8%)
RFA 0 0 0
VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, PSM propensity score
matching, ECOG Eastern Cooperative Oncology Group, TACE transarterial chemoembolization, RFA radiofrequency ablation
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positively considered for patients with sufficient pul-
monary reserve and in a good general condition.
Local recurrence or progression of HCC, history of
liver cirrhosis, and preoperative AFP were found to
be independent prognostic factors. If there is a local
recurrence or progression of HCC or if the level of
AFP before metastasectomy is high, decisions on sur-
gical treatment should be made with caution.
According to the results of the propensity score
matching analysis, VATS metastasectomy provided
outcomes comparable to those afforded by open metas-
tasectomy. The most important prerequisite for pulmon-
ary metastasectomy is complete resection.
Table 8 Surgical characteristics of open and VATS group after propensity score matching
Total (n = 58) Open (n = 29) VATS (n = 29) p value
Preoperative AFP (ng/ml) 6.9 (0.6–12,000.0) 11.6 (1.1–6610.0) 4.7 (0.6–12,000.0) 0.981
Local recurrence 36 (62.1%) 17 (58.6%) 19 (65.5%) 0.373
Progression of local disease 5 (8.6%) 4 (13.8%) 1 (3.4%)
Laterality 0.570
Unilateral 40 (69.0%) 19 (65.5%) 21 (72.4%)
Bilateral 18 (31.0%) 10 (34.5%) 8 (27.6%)
Number of metastasis 1.9 ± 1.4 2.1 ± 1.6 1.8 ± 1.3 0.414
Size (mm) 15.8 ± 8.8 16.9 ± 9.3 14.7 ± 8.2 0.343
Extent of resection 0.025
Wedge resection 46 (79.3%) 19 (65.5%) 27 (93.1%)
Segmentectomy/lobectomy 12 (20.7%) 10 (34.5%) 2 (6.9%)
Hospital stay (days) 6.2 ± 3.7 7.4 ± 3.0 5.1 ± 3.9 0.017
Complications 1 (1.7%) 1 (3.4%) 0 0.313
DFI from HCC (months) 24.0 ± 19.0 21.5 ± 16.0 26.5 ± 21.5 0.312
DFI from PM (months) 16.4 ± 28.0 14.9 ± 26.2 17.9 ± 30.1 0.683
Recurrence after metastasectomy 51 (87.9%) 27 (93.1%) 24 (82.8%) 0.227
Recurrence including PM 40 (69.0%) 23 (79.3%) 17 (58.6%) 0.089
Overall survival time (months) 49.2 ± 37.4 52.5 ± 38.1 46.0 ± 37.0 0.513
VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, PM pulmonary metastasis, DFI disease-free interval
Fig. 3 Survival rate after the first pulmonary metastasectomy in matched group; overall survival rate (a), disease-free survival rate (b), pulmonary
specific disease-free survival rate (c)
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